The influence of protease inhibitor on the progress of bronchial asthma.
Trasylol in a single dose 100000 i.u. was administered intravenously to 22 patients suffering from bronchial asthma. Pulmonary function was evaluated by the subjects self-comfort, physical examination, spirometric measurements (VC, FEV1, FEV1%, MCBind.) and blood gas analysis (pH PCO2, PO2, SaO2). In half of the patients after Trasylol administration, a diminished dyspnoea and bronchospasm were observed. Analysis of blood gases indicated some decrease of PCO2, and an increase of PO2 and pH. In spirometric study no statistically significant differences, either before or after Trasylol administration, were noticed. Trasylol treatment may be applied for asthmatic patients especially those with severe disturbances in gas exchange.
D000136:Acid-Base Equilibrium / Q000187:drug effects; D007611:Aprotinin / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D006801:Humans; D011480:Protease Inhibitors / Q000494:pharmacology; D012119:Respiration / Q000187:drug effects
D011480:Protease Inhibitors; D007611:Aprotinin